Clik here to view.
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License...
SHANGHAI & BARCELONA, Spain EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of multispecific antibodies, and Almirall, a global...
View ArticleClik here to view.
AI Medical Service Inc.与越南领先医疗机构签署联合研究协议
东京 (美国商业资讯)– 专门从事诊断性内窥镜人工智能开发的医疗初创企业AI MEDICAL SERVICE INC.（以下简称“AIM”）与越南胃肠病学和肝病学研究所（以下简称“IGH”）签署了联合研究协议，将于2023年10月27日开始研究活动。AIM是第一家与IGH签署内窥镜人工智能领域联合研究协议的日本公司，而IGH则是迄今为止AIM与之合作的第一家越南研究所1。...
View ArticleClik here to view.
AstraZeneca在第二届研发博士后挑战赛中向来自世界各地新晋科学家的八项创新研究项目提供资助
特拉华州威尔明顿 (美国商业资讯)– AstraZeneca今天宣布了2023年研发博士后挑战赛(R&D Postdoctoral Challenge)的八名优胜者，并同意资助他们在该公司位于英国剑桥、美国盖瑟斯堡或波士顿或瑞典哥德堡的战略研发中心之一担任博士后职位。...
View ArticleClik here to view.
ABION Presents New Efficacy Data for ABN401, a Novel MET TKI for Advanced...
SEOUL, South Korea & BOSTON ABION (KOSDAQ: 203400) today released data from an ongoing Phase 2 trial of ABN401, the company’s wholly owned tyrosine kinase inhibitor intended to treat adult...
View ArticleClik here to view.
アストラゼネカ、第2回R＆Dポスドクチャレンジで世界中の若手研究者に8つの革新的な研究プロジェクトに対する助成金を授与
デラウェア州ウィルミントン （ビジネスワイヤ） — アストラゼネカは本日、2023年のR&Dポスドクチャレンジの受賞者8人を発表し、彼らのポストドクトラルポジションを同社の戦略的なR&Dセンターのうち、イギリスのケンブリッジ、アメリカのゲイザースバーグまたはボストン、またはスウェーデンのヨーテボリで資金提供することが発表されました。...
View ArticleClik here to view.
Avistone Announces Preclinical Results for ANS014004, a Type II c-Met...
BEIJING, China Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results from its...
View ArticleClik here to view.
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large,...
AUSTIN, Texas Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD)...
View ArticleClik here to view.
NEC OncoImmunity publishes research using its neoantigen prediction...
OSLO, Norway NEC OncoImmunity AS (NOI) today announced it has published a study that describes the use of its artificial intelligence (AI) based neoantigen prediction technology to demonstrate that...
View ArticleClik here to view.
Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to...
OXFORD, England & MONROE TOWNSHIP, N.J. Blue Earth Diagnostics Ltd, a Bracco company and recognised leader in the development and commercialisation of innovative PET radiopharmaceuticals,...
View ArticleClik here to view.
Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003...
BEIJING Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), will attend and present a poster at the ESMO Congress 2023, taking...
View ArticleClik here to view.
BeiGene Announces Late-Breaking Data at ESMO Showing Tislelizumab plus...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced results from the final analysis of the...
View ArticleClik here to view.
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Phase 3 RATIONALE 315 study...
View ArticleClik here to view.
NEC OncoImmunity、がん免疫療法を受けた肉腫患者の改善結果を示すネオアンチゲン予測技術を使用した研究を公表
オスロー、ノルウェー （ビジネスワイヤ） — NEC OncoImmunity AS（NOI） は、自社の人工知能（AI）ベースのネオアンチゲン予測技術を用いた研究で、腫瘍の免疫細胞の浸潤と高品質なネオアンチゲンの共存が、免疫チェックポイント阻害療法を受けた肉腫患者の無増悪生存期間（PFS）の改善と関連していることを明らかにしました。...
View ArticleClik here to view.
European Commission Approves ADCETRIS® (brentuximab vedotin) for the...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine...
View ArticleClik here to view.
ImmunoScape Uses Machine Learning to Accurately Predict Antigen Specificity...
SAN DIEGO & SINGAPORE ImmunoScape, a biotechnology company focused on next-generation immunotherapies, published new peer-reviewed research that demonstrates the use of machine learning to...
View ArticleClik here to view.
Daiichi Sankyo and Merck Announce Global Development and Commercialization...
BASKING RIDGE, N.J. & RAHWAY, N.J. Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and...
View ArticleClik here to view.
BRUKINSA® Receives Positive Recommendation from NICE in U.K. for Adult...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the National Institute for Health and...
View ArticleClik here to view.
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity...
TOKYO & BASKING RIDGE, N.J. Updated results from a subgroup analysis of a first-in-human phase 1 trial showed that raludotatug deruxtecan (R-DXd) continues to demonstrate promising clinical...
View ArticleClik here to view.
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients...
TOKYO & MUNICH ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced non-small cell lung cancer...
View ArticleClik here to view.
Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014...
NEWCASTLE, England Iksuda Therapeutics (Iksuda), the developer of class leading antibody drug conjugates (ADCs) with enhanced tumour specificity, today announces that the first patient has completed...
View Article